Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy

Clinical Biochemistry

Volumn 41, Issue 10-11, 2008, Pages 785-795

  You, Benoit ^a,b,c   Perrin, Paul ^c   Freyer, Gilles ^a,b,c   Ruffion, Alain ^c   Tranchand, Brigitte ^a,b,d   Hénin, Emilie ^a,b   Paparel, Philippe ^c   Ribba, Benjamin ^a,b   Devonec, Marian ^c   Falandry, Claire ^a,b,c   Fournel, Cécile ^a,b,c   Tod, Michel ^a,b,e   Girard, Pascal ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d CENTRE LÉON BÉRARD   (France)

^e Institut Cochin   (France)

Author keywords

Biomarker; Kinetics; Metabolite clearance rate; Prostate specific antigen; Prostatectomy; Prostatic hyperplasia

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ANALYTICAL ERROR; ARTICLE; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HALF LIFE TIME; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; METABOLIC CLEARANCE RATE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY;

EID: 46549087597     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.04.001     Document Type: Article

References (33)

1. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
2. Kelloff G.J., Coffey D.S., Chabner B.A., et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 10 (2004) 3927-3933
3. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42-S46
4. Eastham J.A. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer. Nat Clin Pract Urol 2 (2005) 482-491
5. Maffezzini M., Bossi A., and Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol 51 (2007) 605-613
6. Haab F., Meulemans A., Boccon-Gibod L., Dauge M.C., Delmas V., and Boccon-Gibod L. Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Prostate 26 (1995) 334-338
7. Ravery V., Meulemans A., and Boccon-Gibod L. Clearance of free and total serum PSA after prostatic surgery. Eur Urol 33 (1998) 251-254
8. Vollmer R.T., and Humphrey P.A. Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. Am J Clin Pathol 119 (2003) 80-89
9. Lein M., Brux B., Jung K., et al. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. Eur J Clin Chem Clin Biochem 35 (1997) 591-595
10. May M., Gunia S., Helke C., Braun K.P., Pickenhain S., and Hoschke B. Is it possible to provide a prognosis after radical prostatectomy for prostate cancer by means of a PSA regression model?. Int J Biol Markers 20 (2005) 112-118
11. Stamey T.A., Kabalin J.N., McNeal J.E., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141 (1989) 1076-1083
12. van Straalen J.P., Bossens M.M., de Reijke T.M., and Sanders G.T. Biological half-life of prostate-specific antigen after radical prostatectomy. Eur J Clin Chem Clin Biochem 32 (1994) 53-55
13. Brandle E., Hautmann O., Bachem M., et al. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy-a critical assessment. Urology 53 (1999) 722-730
14. Gregorakis A.K., Malovrouvas D., Stefanakis S., Petraki K., and Scorilas A. Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy. Clin Chim Acta 357 (2005) 196-201
15. Oesterling J.E., Chan D.W., Epstein J.I., et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 139 (1988) 766-772
16. Sheiner L.B. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 15 (1984) 153-171
17. Rowland M., Rowland R., and Tozer. Clinical pharmacokinetics: concepts and applications. Sub 3 (1995) (mai 1995)
18. Kuritzky L. Role of primary care clinicians in the diagnosis and treatment of LUTS and BPH. Rev Urol 6 Suppl 9 (2004) S53-S59
19. Millin T. Retropubic prostatectomy: a new extravesical technique report on 20 cases. 1945. J Urol 167 (2002) 976-979
20. Beal S., and Sheiner L. NONMEM users guides (1992)
21. Dartois C., Brendel K., Comets E., et al. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol 64 5 (2007) 603-612
22. Brendel K., Dartois C., Comets E., et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46 (2007) 221-234
23. Yano I., Beal S.L., and Sheiner L.B. The need for mixed-effects modeling with population dichotomous data. J Pharmacokinet Pharmacodyn 28 (2001) 389-412
24. Yano Y., Beal S.L., and Sheiner L.B. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28 (2001) 171-192
25. Oudard S., Banu E., and Scotte F. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate caner patients. Ann Oncol (2007) 1828-1833
26. Vozeh S., Steimer J.L., Rowland M., et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 30 (1996) 81-93
27. Marks L.S., Dorey F.J., Rhodes T., et al. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J Urol 156 (1996) 1035-1039
28. Vollmer R.T., and Humphrey P.A. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. Am J Clin Pathol 116 (2001) 864-870
29. Furuya Y., Akakura K., Ichikawa T., Masai M., Igarashi T., and Ito H. Effect of prostatic biopsy on free-to-total prostate-specific antigen ratio in patients with prostate cancer. Int J Urol 7 (2000) 49-53
30. Hammerer P.G., McNeal J.E., and Stamey T.A. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 153 (1995) 111-114
31. Lloyd S.N., Collins G.N., McKelvie G.B., Hehir M., and Rogers A.C. Predicted and actual change in serum PSA following prostatectomy for BPH. Urology 43 (1994) 472-479
32. Recker F., Kwiatkowski M.K., Pettersson K., et al. Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia. Eur Urol 33 (1998) 549-555
33. Aus G., Bergdahl S., Frosing R., Lodding P., Pileblad E., and Hugosson J. Reference range of prostate-specific antigen after transurethral resection of the prostate. Urology 47 (1996) 529-531